ASCO GU Symposium 2024: Focus on Prostate Cancer
Advertisement
The study analyzed VISION-eligible patients with mCRPC who were classified as TheraP-eligible or ineligible.
The study is the first large-scale report of patients in the United States treated with 177Lu-PSMA-617.
Dr. Wallis highlights his population-based research on treatment intensification shortcomings in de novo mCSPC.
Dr. Eggener describes the Stockholm3 test and reasons for validating it in an ethnically-diverse population.
Drs. Barata and Wallis discuss the interaction of age and benefit of treatment intensification in advanced prostate cancer.
Drs. McGregor and Wallis highlight CONTACT-2, the first study of an ICI-based regimen to show improvement in rPFS in PC.
HRQoL was maintained in the niraparib plus AAP arm, and patients experienced minimal side effect bother from treatment.
Dr. Moul details his research involving African American patients and those with high BMI and their response to ADT.
The enzalutamide group experienced a significant deterioration in mean fatigue changes when compared with the AA group.
Dr. Moul offered his insights on how prostate cancer MRI and PSMA PET compare in terms of utility and sensitivity.
Drs. Hoffman and Wallis discuss the HRQoL from FORMULA-509 trial, showing no difference in hormonal function and fatigue.
Researchers investigated the combination's effect on fatigue, cognitive impairment, and sexual function.
Dr. Maha Hussain presented results of the BRCAAway trial in patients with mCRPC who have HRR mutations.
Researchers noted significant differences in prostate cancer-specific survival and overall survival.
Cabozantinib plus atezolizumab improves rPFS versus second NHT in patients who had progressed on a prior NHT and have mCRPC.
Researchers evaluated real-world survival for patients with mCSPC who received enzalutamide or apalutamide treatment.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.